Kai Pharmaceuticals


KAI Pharmaceuticals is a drug discovery and development company with clinical and preclinical therapeutic programs for the acute treatment of ischemia and reperfusion injury and for diseases involving chronic regulation of angiogenesis. The company is applying its core expertise in the biology of specific protein kinase C (PKC) isozymes to develop highly specific activators and inhibitors of PKC isozymes for the treatment of a variety of human diseases. KAI has received ‘Fast Track’ designation for its lead drug candidate, KAI-9803, currently being investigated in a Phase I/II clinical trial as a treatment to reduce reperfusion injury as an adjunct to current treatments for acute myocardial infarction, or heart attack.


Date Type Amount Investors Valuation
05/02/06 Series B 35M Aberdare Ventures, Delphi Ventures, Intersouth Partners, InterWest Partners, Investor Growth Capital, MDS Capital, Skyline Ventures, Thomas Weisel Venture Partners Unknown


Stephen Harrison (VP Research)

Daria Mochly-Rosen (Professor)

Natalie Holles (Sr. Director of Business Development)

Yasunori Kaneko (Board Member)

View more details about all 15 people at Kai Pharmaceuticals